<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56641">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368743</url>
  </required_header>
  <id_info>
    <org_study_id>000179</org_study_id>
    <nct_id>NCT02368743</nct_id>
  </id_info>
  <brief_title>QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)</brief_title>
  <acronym>QUARTZ</acronym>
  <official_title>QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This national, observational and multicentre study aims at establishing a picture of real
      clinical practices management among patients treated with Pentasa®, according to the current
      therapeutic strategy in ulcerative proctitis. This study should be able to provide data on
      patients' health related quality of life, compliance and efficacy in real clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score</measure>
    <time_frame>From baseline to week 8</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Active Ulcerative Proctitis</condition>
  <arm_group>
    <arm_group_label>mesalazine</arm_group_label>
    <description>Treatment according to standard clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalazine</intervention_name>
    <arm_group_label>mesalazine</arm_group_label>
    <other_name>Pentasa®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Gastroenterologists with private and/or hospital practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or older.

          -  Patient suffering from mild to moderate active proctitis (MAYO score ≥ 3 and ≤ 10) at
             inclusion based on clinical and endoscopic findings within one month before study
             inclusion

          -  Patient with evidence of endoscopic active proctitis (Montreal classification E1
             defined by an involvement limited to the rectum that is, proximal extent of
             inflammation is distal to the rectosigmoid junction) within one month before study
             inclusion.

          -  Patient for whom the investigator has decided to start during the inclusion visit a
             treatment of the current flare with Pentasa® to induce a remission.

          -  Patient having received oral and written information on the study, without any
             objections for the use of his/her personal data, and having signed a written Informed
             Consent Form.

        Exclusion Criteria:

          -  Patient included in an interventional study assessing treatment for active proctitis

          -  Patient with left sided, sigmoiditis or pancolitis.

          -  Patient with severe proctitis (MAYO score ≥ 11 at inclusion).

          -  Patient previously treated with biologics.

          -  Patient treated with immunosuppressive within 1 month before study inclusion.

          -  Patient treated with corticosteroids within 2 weeks before study inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastro-Entérologie et Hépatologie - CHU Brabois (there may be other sites in this country)</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 21, 2016</lastchanged_date>
  <firstreceived_date>February 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
